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Invasive Candida infections 
in the nursery: state of 
the art
ABSTRACT
Neonatal sepsis caused by fungi (mainly Candida spp.) causes a huge burden of morbidity and mortality, poor late outco-
mes, as well as increased hospital costs. 
Invasive Candida Infections (ICI) include bloodstream, urine, cerebrospinal, peritoneal infections, infections starting from 
burns and wounds, or from any other usually sterile site.
Premature neonates are particularly prone to this kind of disease, due to their decreased innate and adaptive immunities, 
translating into a specific, decreased resistance to candidiasis.
This specific, increased risk for ICI is greatest when gestational age and birth weight are lowest. As the burden of ICI has 
been increasing over the last years, research efforts have been focused towards identifying key risk factors, effective pre-
ventative strategies, and efficacious and well-tolerated antifungal drugs for the neonatal population.
This article summarizes the most remarkable issues in these areas, and features an overview of the current diagnostic, 
preventative and treatment strategies.
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Introduction 
The background on 
neonatal invasive 
Candida infections
The progress in neonatal care has led 
to an ever-increasing number of pre-
term neonates surviving to the most 
extreme degrees of prematurity, thus 
in need of aggressive care in neonatal 
intensive care units (NICUs). (1)
These neonates are affected by a num-
ber of innate immunity impairments 
occurring in the early phases of their 
extrauterine life, therefore during their 
stay in the NICU.
Both prematurity and immunity defects 
determine an enhanced specific risk 
for development of fungal colonization 
and systemic infections that are typical 
for all preterms, being greatest when 
gestational age and birth weight are 
lowest.
Overall, most preterm neonates in 
NICU may feature a number of specific 
risk factors for fungal colonization and 
infection. 
An impaired activity of the gastric acid 
barrier, often enhanced by the use of 
H2-blockers, decreases the ability of 
the stomach to stop the passage of 
pathogens from the upper digestive 
tract to the gut. 
Lack of fresh maternal milk, a frequent 
occurrence in preterm neonates fed by 
parenteral nutrition since they have poor 
ability to tolerate oral feeds, deprives 
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the infants of important bioactive fac-
tors that can provide consistent anti-
infective actions. The immaturity of the 
gut, often associated with an increased 
permeability of the gut wall, decreases 
the ability of the infant to defend itself 
against pathogens at the intestinal 
level, and –as a result- many of these 
pathogens may translocate from the 
gut lumen to the bloodstream.
In addition, loss or paucity of  gut com-
mensals such as Bifidobacteria and 
Lactobacilli, as occurs with prolonged 
antibiotic treatment, delayed enteral 
feeding, or nursing in incubators, trans-
lates into proliferation of pathogenic 
microflora and abnormal gut coloni-
zation, thus enhancing breakthrough 
colonization in the gut by many patho-
gens, including Candida spp. (2)
It has been said that invasive Candida 
infections (ICI) in preterm neonates 
follow the “90% rule”: more than 90% 
of neonatal ICIs are caused by Can-
dida spp. (with only scattered cases 
attributable to Aspergillus spp.), more 
than 90% occur in premature neonates 
rather than term, and more than 90% 
are acquired in the NICU, with only a 
minority of them originating from verti-
cal transmission. (3) 
ICI are severe, and ICI-related mortality 
is still unacceptably high (up to 30%, 
compared with some 77% for invasive 
fungal infections caused by Aspergillus 
spp.). (4)
Contrary to other high-risk patients, in 
preterm neonates the risk condition 
for fungal and Candida infections is 
destined to vanish as days of stay in 
the NICU go by. 
Availability of mother’s fresh milk, and 
ability of the neonate to tolerate it as 
he gets older, is critical since maternal 
fresh milk provides innate defenses that 
may be helpful to overcome the risky 
time-window. Moreover, the achieve-
ment of the ability of tolerating the with-
drawal of central vascular catheters 
(CVC) removes from these patients the 
risk of hub colonization, and hence the 
formation of septic thrombi and biofilms 
that may be reservoires for systemic 
spread even after the risky time-window 
is over.
Of note, suboptimal perinatal bacte-
rial colonization is probably the most 
important risk factor for Candida inva-
sive infections in preterm neonates. 
(5-7)
Invasive microorganisms including 
fungi may be encouraged by the use 
of antibiotics in the mother before birth 
and the use of broad spectrum antibi-
otics in neonates. Sometimes fungal 
colonization in preterms occurs due 
to vertical transmission from the moth-
er but, (8) most frequently horizontal 
transmission occurs within the NICU. 
(1) This latter modality could particu-
larly explain the great differences in the 
incidence of fungal infection between 
European NICUs as there is great vari-
ability in terms of antibiotic prescription 
and overall nursing management.
As for diagnosis, blood culture is the 
gold standard but might not be fully 
reliable in these particular patients 
and settings, as its sensitivity is poor, 
thus translating into frequent negative 
results that might not correctly repre-
sent the true diagnostic picture. Limited 
sensitivity of blood cultures in neonates 
depends on inadequate blood volumes 
collected, transient candidaemic phas-
es, or frequent shedding of the fungal 
colonies in the biofilms rather than in 
the bloodstream. 
In neonatal ICI, systemic dissemination 
may occur in every organ, and the risk 
of central nervous system involvement 
is higher given the high neonatal per-
meability of the haemato-encephalic 
barrier.
Neurodevelopmental sequels are 
severe and frequent, as they may occur 
even when the ICI has been properly 
treated. Poor late outcome is typically 
associated with Candida spp. infec-
tions rather than with infections caused 
by other pathogens. (7)
In view of the above considerations, the 
best option for decreasing the burden 
of the disease is to avoid it with specific 
prophylaxis. 
Prevention- current 
strategies
As mentioned above, prompt diagnosis 
and effective treatment do not protect 
preterm neonates in the intensive care 
unit (ICU) from the risk of late neurode-
velopmental impairment in the survi-
vors, (7) thus prevention of Candida 
infection is the key in these setting of 
unique patients.
In view of this, improving neonatal man-
agement is a key step, and this includes 
promotion of fresh, human milk feeding, 
implementation of hygiene measures, 
cautious CVC management, enhance-
ment of the enteric microbiota compo-
sition with the use of specific strains of 
probiotics, and medical stewardship 
concerning H2-blockers and steroid 
restrictions. 
Substantial results in decreasing the 
rates of ICI have been achieved with 
the use of fluconazole. This azole may 
be administered either intravenously or 
orally, and proved effective in reducing 
the rates of colonization and infection 
by 80% in very low birth weight (VLBW) 
and extremely low birth weight (ELBW) 
infants. (6) In the literature, more than 
2,500 preterm VLBW infants receiving 
fluconazole have been studied, and 
no serious adverse effects have been 
described, thus vouching for substantial 
safety of this strategy. Adoption of wide-
spread use of prophylactic fluconazol, or 
at least in the NICUs with highest rates of 
ICI, would translate into a considerable 
reduction of the burden of ICI, of the ICI-
related hospitalization costs, and (most 
of all) could deliver increased and better 
health to thousands of premature infants 
every year. (6)
A new approach towards reduction of 
sepsis and necrotizing enterocolitis 
(NEC) might involve the use of bioac-
tive substances with known anti-infec-
tive properties. Lactoferrin is a mam-
malian milk glycoprotein involved in 
innate immune host defences, and can 
reduce the incidence of late-onset sep-
sis in VLBW infants (9) and of NEC in 
animal models. The bovine isoform is 
nearly homologous to the human one. 
Lactoferrin targets all pathogens, has 
bifidogenic properties, and enhance 
maturation of the nascent gut.
In a recent randomized controlled trial, 
bovine lactoferrin produced a 65% 
decrease in any-cause Late-Onset Sep-
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sis (LOS), and a significant decrease 
in both surgical and low-stages NEC. 
(10)
As no adverse effects or intoleranc-
es to treatment have been reported 
to date, the role of lactoferrin in the 
management of infections and NEC in 
NICU looks very promising and worthy 
of future, larger-sized trials to confirm 
these findings.
Treatment - 
Current strategies
When prevention has not been per-
formed, or when the goal of prevention 
has been not achieved, and the preterm 
neonates faces an ICI, the optimal res-
cue strategy would be to perform treat-
ment with the most potent antifungal 
available, in order to minimize the risk 
of septic foci escaping treatment and 
disseminating subsequently to organs 
or cause neurodevelopmental impair-
ments.
It has been said that the best strategy is 
“hit fast, hit hard“, because of the risks 
inherent to persistence of circulating 
fungal colonies in the bloodstream, 
or that fungal septic foci could remain 
shed in organs or within the biofilms 
– a risk that absolutely needs to be 
avoided.
Promptness is the keyword for the treat-
ment of preterm neonatal ICI, and the 
most correct approach is immediate 
treatment with documented infection. 
From retrospective data, this approach 
has been demonstrated in several stud-
ies to improve outcomes.  
When detecting candidemia, early 
removal of a CVC is mandatory since 
the catheter tip might be colonized and 
biofilm formation could have occurred. 
Since fungal colonies nested in bio-
films can prevent clearance of infection, 
the common recommendation is for 
removal until clearance of candidemia 
for >3 days documented by daily cul-
tures.  At that time reinsertion of a CVC 
may be considered.  It is also impor-
tant to remember that delayed central 
catheter removal with candidaemia is 
associated with worse outcomes and 
increased mortality. (11) 
Of course, maintenance of a CVC 
is often critical in premature infants, 
but it is rare that the CVC cannot be 
removed if needed.   If the “loss” of cen-
tral venous access may indeed result 
in problems for a critical neonate in 
whom it may prove impossible to install 
another CVC, then the usual advice is to 
quickly remove it and to replace it with 
another (in another site), provided that 
at least two bolus-doses of a systemic 
antifungal have been administered in 
the meanwhile. 
When a positive result from blood 
cultures is not available, decision on 
whether to institute or not a specific 
antifungal treatment should be based 
on a comprehensive assessment of the 
clinical picture, of the laboratory mark-
ers, and of the ecological pre-existing 
situation. (12)
The use of fungal colonization informa-
tion may often aid in decision making 
regarding empirical therapy.  Empirical 
therapy for 48-72 hours while awaiting 
culture results in symptomatic high risk 
patients is often used to deliver early, 
appropriate therapy to these vulnerable 
hosts. (13)
Some indentified risk factors that can 
be combined with clinical symptoms 
of infection include: <27 weeks gesta-
tion, exposure to 3rd or 4th generation 
cephalosporin or carbapenems in the 
previous 7 days, new onset thrombo-
cytopenia, and/or with symptoms of 
sepsis despite 48 hours of antibacte-
rial treatment. While empiric therapy is 
often advocated, little data is available 
and it has not been subjected to rigor-
ous controlled trials.  
Mention has already been made of the 
non-total reliability of blood cultures 
and the fact that as many as 72 hr may 
be needed to secure the growth of Can-
dida. A delay of this kind is obviously 
unacceptable in the management of 
the patients. (14)
Prompt, empirical treatment is impera-
tive for non-immunocompetent sub-
jects such as preterm neonates, since 
Candida-associated mortality is as high 
as 38% and rises to 50% in those who 
start antifungal therapy more than two 
days after the first positive blood cul-
ture. (15)
It is useful to underline once more that 
–either in the case of targeted treatment 
or of empirical treatment - the prefer-
able antifungal drugs must have signifi-
cant activity against biofilms, as well as 
activity against C. glabrata, C. tropicalis 
and C. krusei, i.e. the species that may 
survive prophylactic fluconazole 
Historically, the first options in the treat-
ment of neonatal ICI have been –and 
currently are- fluconazole and ampho-
tericin B. Indeed, their use in neonates 
is hampered by lack of sufficient phar-
macokinetic data (PK) which gives rise 
to a risk of inappropriate response to 
treatment. Moreover, these two drugs 
carry limitations both in efficacy and in 
putative toxicity. 
Fluconazole is poorly active against 
some Candida spp. strains that are 
quite frequently retrieved from neonates 
(e.g., C. glabrata and C. krusei). In addi-
tion, it is not reasonable to use such an 
azole for treatment in all cases in which 
it has already been used for prophy-
laxis: if prophylactic fluconazole failed, it 
is highly unlikely that therapeutic flucon-
azole can work. Or –at the very least – it 
is not appropriate to run this risk, since a 
“wait-and-see” approach is not correct 
in such a severe disease. (16)
On the other hand, amphotericin B 
would be a reasonable first-choice 
option as empirical treatment for a 
VLBW neonate with clinical deterio-
ration and signs of sepsis who does 
not respond to the optimum antibiotic 
empirical treatment. (2) 
However, in spite of some reassuring 
data, (17) amphotericin B has some 
renal and bone marrow toxicity that has 
never been subjected to well-designed, 
prospective safety trials in neonates.
Recently, new therapeutic alternatives 
have drawn the neonatologists’ atten-
tion. The Echinocandins (Caspofungin, 
Micafungin, Anidulafungin) are a new 
class of antifungal drugs with char-
acteristics that might better meet the 
needs of this particular population of 
patients. These products are broad-
spectrum antifungal agents that have 
been shown effective for treatment of 
invasive aspergillosis, oesophageal 
candidiasis and other invasive Candida 
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infections in adults, and (for Micafun-
gin) in children including infants. (18) 
Moreover, their safety profile is reported 
as more favourable than conventional 
or liposomal amphotericin B, with less 
drug-related adverse events, less infu-
sion-related events, and less nephro-
toxicity. Recent new data confirmed this 
overall good safety profile for Micafun-
gin. (19,20) Echinocandins have there-
fore become an attractive option for 
first-line treatment in all paediatric and 
neonatal patients affected by Candida 
and/or Aspergillus systemic infections, 
and – as a matter of fact - Micafungin 
is, as-of-today, the only antifungal drug 
authorized for neonatal use by the EMA 
– European medicines agency. (21)
Conclusion
Management and prevention of neo-
natal ICI is a challenge for every neo-
natologist. 
Specific education and skil ls are 
required to properly address diagnos-
tics, use of laboratory information, and 
choice of the correct antifungals, timing 
and duration of treatment. 
Nonetheless, most ICI could be avoid-
ed if only prophylaxis with fluconazole 
could be instituted in every high-risk 
neonate, or neonatal setting.
Clearly, advocacy for such objectives 
needs to become inherent to the mis-
sion and to the ethical approach of all 
neonatologists and neonatal nurses.
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